What is Perihilar Cholangiocarcinoma (Klatskin Tumor)?

Receiving a diagnosis of perihilar cholangiocarcinoma (pCCA), sometimes called a Klatskin tumor, is understandably overwhelming. You are likely feeling a mix of shock and fear. It is important to know that while this is a rare and aggressive cancer with a challenging prognosis, the field of hepatobiliary (liver and bile duct) medicine has advanced in recent years ^[1]. You are not just a statistic, and there are structured pathways for your care.

Understanding the “Plumbing” of the Liver

To understand this diagnosis, it helps to think of your liver and bile ducts as a complex plumbing system. Your liver constantly produces bile, a fluid essential for digesting fats.

This fluid flows through a network of small tubes that eventually merge into two main pipes: the right and left hepatic ducts. The point where these two pipes join to exit the liver and head toward the intestines is called the hilum ^[1].

• Perihilar means “around the hilum.”
• Klatskin tumor is the historical name for a cancer that starts exactly at this critical Y-junction ^[1].

Because the tumor sits at this vital intersection, even a very small growth can block the flow of bile from both sides of the liver. When these “pipes” are blocked, bile backs up into your bloodstream, which often causes jaundice (yellowing of the skin and eyes) and intense itching ^[2].

How Common is This?

Perihilar cholangiocarcinoma is considered a rare disease ^[1]. While all forms of bile duct cancer are uncommon, pCCA is the most frequent type of extrahepatic (outside the liver) cholangiocarcinoma, accounting for roughly 50% to 60% of cases ^[1]. Because it is rare and technically complex to treat, it is crucial to be seen at a specialized center ^[3].

Three Stabilizing Facts

While the diagnosis is serious and the surgery carries high risks, three major pillars of modern medicine provide a framework for care:

1. The Multidisciplinary Advantage: Current guidelines emphasize the Multidisciplinary Tumor Board (MDT)—a team of surgeons, oncologists, and radiologists who review your case together ^[3]. Treatment determined by a team specializing in liver and bile duct diseases helps ensure all options are considered ^[4].
2. Expanded Curative Pathways: For some highly selected patients whose tumors cannot be removed by standard surgery, the Mayo Clinic Protocol offers a path to a liver transplant ^[5]. While eligibility is extremely strict, this protocol (involving chemoradiation followed by a transplant) has achieved a 5-year survival rate of approximately 52% in qualifying patients ^[5].
3. Molecular Precision: Doctors increasingly use molecular profiling to test the tumor’s DNA ^[6]. While “targetable” mutations are less common in perihilar tumors compared to other types of liver cancer, identifying specific markers (like MSI-High status) can sometimes open the door to modern immunotherapies ^[7][6].